9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Estimated reading time: < 1 min

Condition: Malignant Pleural Disease

Estimated Enrollment: 66

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Composite measure of severity and number of adverse events (AEs); changes in clinical laboratory test findings (hematologic and chemistry); and physical examination.,  Changes in serum levels of the biomarker soluble mesothelin related peptide (SMRP),  ,

Interventions: iCasp9M28z T cell infusions, cyclophosphamide

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: April 2020

Completion Date: April 2020

Last  Posted Date: May 17, 2019

Location: Memoral Sloan Kettering Basking Ridge (Sceening Consent only), Basking Ridge, New Jersey, United States

Website Link: https://ClinicalTrials.gov/show/NCT02414269

Was this article helpful?
Dislike 0